Internet Program for Cancer Pain Management
This study is testing an 8-session internet-based pain coping skills program to help cancer survivors manage ongoing pain. You may be able to join if you are an adult (18 years or older) with a documented diagnosis of invasive cancer that has been treated. This program aims to improve how severe your pain is and how much it interferes with your daily life. The study is comparing this internet program plus usual care to usual care alone. The current recruitment status is unclear.
- Study design
- This is a randomized controlled study, meaning participants are assigned by chance to one of two groups. It plans to enroll 250 participants.
- What's involved
- Each participant will be in the study for 9 months, from when they are assigned to a group until the final follow-up assessment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 9 months after randomization, with pain severity and interference measured at 10 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04462302
An Internet-based Program to Help Cancer Survivors Manage Pain
Active, Not Recruiting
NAAges 18+InterventionalSupportive careWake Forest University Health SciencesInvestigator-initiated
~456 participants
Updated 2026-08-11 on ClinicalTrials.gov
What's tested:Internet-based pain coping skills program
At a glance
Recruiting sites
0 of 150 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pain Severity
Measured over Change from Baseline to 10 week
+1 more outcome measured
Conditions
Where it's being run
150 sites across 21 statesCalifornia21
Illinois18
Hawaii15
South Carolina12
Minnesota11
Wisconsin11
Michigan10
Iowa8
Study leadership
- Glenn Lesser, MD · STUDY_CHAIR · Wake Forest University Health Sciences
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
May be either off all treatment OR actively receiving anticancer therapy in an adjuvant setting, maintenance setting, or for active cancer.
Patients who currently undergoing anticancer therapy should not have any plans to change or adjust their treatment during the intervention period. This includes changing to another therapy or ending therapy entirely.
Patients who are currently receiving anticancer therapy at the screening process must have been on current therapy for at least four weeks. Alternatively, if they are planning to discontinue therapy before enrolling, they must have been off therapy for four weeks prior to enrollment.
A minimum of four weeks must have elapsed since the most recent MAJOR surgical intervention.
A minimum of two weeks must have elapsed since the most recent MINOR surgical procedure (e.g., port placement).
In addition, eligible patients must not have a planned surgical procedure or course of radiation therapy during the 3-month study intervention period (i.e., the three months leading up to primary outcome evaluation-timepoint.
Patients who are no longer receiving anticancer therapy must be less than/equal to 5 years since the completion of their anticancer therapy (e.g., time since the last day of chemotherapy administration, time since last day of radiotherapy, etc.).
Must have pain indicated by a score of ≥ 4 on PROMIS Pain Intensity (1a) scale, using the Pain Eligibility Interview.
Must have a score of "Most Days" or higher on the Graded Chronic Pain Scale Revised (Abbreviated) using the Pain Eligibility Interview.
Patients do not have to be on analgesic medications of any kind in order to participate. If they are taking analgesics, they must be on a stable analgesic regimen (i.e., no changes to the prescribed analgesic regimen) over a period of at least 14 days prior to enrollment. Eligible patients should not have planned upward dose titration of their analgesics during the 3-month study intervention period (i.e., the three months leading up to primary outcome evaluation timepoint. Patients may elect to decrease their analgesic use during the study as per discussions with their provider. Unexpected dose adjustments including dose escalations as a result of unforeseen clinical need is allowed in all patients at all times during the study. Cannabis prescribed for medicinal purposes would qualify as an analgesic in this context.
Must have pain of new onset or significantly exacerbated since the time of cancer diagnosis or initiation of cancer treatment
Must be expected to be able to complete all study activities including the 22- and 34-week follow-up assessments according to the treating/referring clinician (e.g., treating clinician feels the patient is unlikely to develop progressive disease requiring additional active cancer therapy through the 6-month follow-up period).
ECOG performance status of 0, 1, or 2.
Age ≥18 years at the time of study entry
Must be able to speak, read and understand English.
Exclusion
Has a disability that precludes completion of study activities (e.g., severe vision or hearing impairment, diagnosis of dementia or clinical evidence of severe cognitive impairment, diagnosis or clinical evidence of severe psychiatric disorder, or diagnosed drug or alcohol abuse disorder), as per patient report or documented in the medical record.
Reports only preexisting pain conditions unrelated to cancer or cancer treatment (e.g., migraine or tension headache, arthritis, back disorders, bursitis/tendonitis, injuries, fibromyalgia).
Has a known or suspected diagnosable substance use disorder or opioid overuse disorder (according to DSM-5 criteria), or is actively receiving treatment for a substance use disorder, as per patient report or documented in the medical record.
Currently being prescribed buprenorphine or suboxone.
Patients enrolled on hospice care or end-of-life palliative care are not eligible for enrollment. Patients whose local care network provides an opportunity for palliative (symptom management) or supportive care concurrent with active treatment following diagnosis (i.e. not solely as a palliative or end-of-life measure) are considered eligible for this study.
Does not have reliable access to Internet or sufficient personal data plan, and is not willing to participate in the Tablet Lending Program provided for this study.
Does not have a working email address.
What this trial measures
- Pain SeverityChange from Baseline to 10 week
The Pain Severity via Brief Pain Inventory (BPI) subscale score is the mean of 4 items measuring current pain, pain on average, and pain at its worst and least in the past 7 days on a scale from 0 (no pain) to 10 (pain as bad as you can imagine).
- Pain InterferenceChange from Baseline to 10 week
The Pain Interference via Brief Pain Inventory (BPI) subscale score is the mean rating of 7 items measuring impact of pain on walking, work, mood, enjoyment of life, relations with others, sleep, general activity on a scale from 0 (does not interfere) to 10 (completely interferes).